Facts and figures

HeadquarterDenmark
InternationalInternational production facilities in seven countries.
Affiliates or offices in 75 countries.
WorkforceApproximately 40,700 employees (June 2014).
Approximately 42% of employees are located in Denmark (17,202) and 58% in the rest of the world (North America: 6,533, Japan & Korea: 1,083, China: 5,045, International Operations: 6,492, Europe: 4,361).
18% within research and development
29% in production and production administration
36% in international sales and marketing
17% in administration
Product areas We have four product areas:
Diabetes care 
Haemostasis management (NovoSeven®) 
Growth hormone therapy 
Hormone replacement therapy (HRT)

According to applicable law, only health care professionals are allowed to access the product information on our site. You can find the information under the Health Care Processionals in the top menu. For patient and disease information, look under Patients. 
Q2 sales*21,629
Annual sales**83,572 (See Annual Report for more information)
Sales by business segment* Diabetes care 17,057
Biopharmaceuticals 4,572
Sales by region* Europe 4,989
North America 10,561
International Operations 2,968
China 1,947
Japan & Korea 1,164

Notes
* million Danish kroner, Q2 results 2014
** million Danish kroner, full year results 2013

Novo Nordisk A/S
Bagsværd, Denmark, 
CVR nr. 24 25 67 90

  •  


  •  
  •  

Share information

Learn more about Novo Nordisk shares.

Shareholder rights


  •  
  •  

Novo Nordisk products

Facts about Novo Nordisk products

Product facts

  •